Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight

Coch, Reilly W.; Green, J.B.

doi:10.1016/j.numecd.2016.06.004

Cited by 11 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pharmacological management of type 2 diabetes is entering a challenging era. Several classes of novel antidiabetic agents entered the market in the past decade: they have been tested not only for their ability to improve glycemic control, but also to demonstrate beneficial or at least neutral effects on cardiovascular (CV) outcomes [1].…”

Section: Introductionmentioning

confidence: 99%

Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems

Raschi

Parisotto

Forcesi

et al. 2017

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems

Raschi

Parisotto

Forcesi

et al. 2017

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

“…Thus, factors other than hyperglycemia may contribute to cardiovascular risk in patients with DM [ 18 , 19 ]. Recent trials have also demonstrated that hypoglycemic agents had direct cardiovascular effects in addition to the glucose lowering effects [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Protective effect of metformin against retinal vein occlusions in diabetes mellitus – A nationwide population-based study

et al. 2017

View full text Add to dashboard Cite

Previous studies have found that metformin can reduce cardiovascular risk, but its association with retinal vein occlusion (RVO) is unknown. In this population-based cohort study using the Taiwan National Health Insurance Research Database (NHIRD), we demonstrated the protective effect of metformin against RVO in diabetes mellitus (DM) and explored the incidence rate and factors associated with RVO development in general and diabetic populations. One million patients were randomly selected from the registry files of the NHIRD, and all their claims data were collected for the 1996–2011 period. Patients with a new diagnosis of central or branch RVO were identified using International Classification of Disease codes. DM was defined for patients with diagnoses and treatments. Factors associated with RVO development in the non-DM and DM cohorts were explored using Cox proportional regression models. In total, 1,018 RVO patients were identified from the database. The average incidence of RVO was 9.93 and 53.5 cases per 100,000 person-years in the non-DM and DM cohorts, respectively. Older age, DM, hypertension, and glaucoma were significant risk factors for RVO, whereas the prescription of anticoagulants was a significant protective factor. In the DM cohort, older age, hypertension, and diabetic retinopathy were significant risk factors for RVO, whereas metformin treatment was a significant protective factor. These results confirmed the risk factors for RVO and demonstrated the protective effect of metformin against RVO in DM patients. Prescribing metformin for DM patients may be beneficial for reducing the incidence of RVO, along with its hypoglycemic action.

show abstract

“…Известно, что основные нарушения метаболизма, характерные для сахарного диабета, приводят в конечном итоге к дегенерации периферических нервов и снижению проводимости по нервным волокнам, что в ряде случаев приводит к нарушениям регуляции кровоснабжения пораженных тканей [1][2][3][4]. Несмотря на всю важность проблемы диабетических ангиопатий, звенья патогенеза сосудистых и в особенности микрососудистых нарушений до настоящего времени исследованы недостаточно.…”

Section: Introductionunclassified

Структурные И Функциональные Нарушения В Микроциркуляторном Русле При Эндокринной Патологии: Методические Рекомендации По Внедрению Результатов Научно-Поисковой Работы

Косякова¹,

Прохоренко²,

Радзюкевич³

et al. 2021

View full text Add to dashboard Cite

В методических рекомендациях проведено исследование периферической микрогемодинамики в коже верхних и нижних конечностей у условно здоровых испытуемых и больных с эндокринной патологией (сахарный диабет второго типа – СД 2) в условиях покоя и в ответ на ортостатическую пробу, с целью выявления вкладов центральных и локальных механизмов в регуляцию периферического кровотока. Показано, что метод ЛДФ позволил исследовать как усредненный показатель микроциркуляции, так и его колебания в широком диапазоне частот. Выявленные изменения показателей МЦР позволили индивидуализировать прогноз риска прогрессирования осложнений СД 2 и при сочетании его с АГ. Наиболее значимые нарушения в МЦР коррелировали с повышением уровня провоспалительных цитокинов, особенно с уровнем IL-6 как у больных с СД 2, так и у больных с СД 2 и АГ. Установлено, что уровень гликированного гемоглобина коррелировал с повышенным уровнем IL-6, что может служить предиктором более тяжелого течения осложнений СД 2 и АГ. Полученные данные исследования могут быть использованы в работе врачей эндокринологов, терапевтов, хирургов, как в амбулаторных условиях, так и в условиях стационаров.

show abstract

Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight

Cited by 11 publications

References 30 publications

Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems

Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems

Protective effect of metformin against retinal vein occlusions in diabetes mellitus – A nationwide population-based study

Contact Info

Product

Resources

About